Management of In Situ Melanoma Diagnosed with Shallow Biopsy

Introduction to Management

The American Academy of Dermatology recommends proceeding with wide excision using 0.5-1.0 cm margins for in situ melanoma diagnosed with shallow biopsy, but considers performing a narrow-margin re-excision first to ensure accurate staging before definitive wide excision 1, 2

A shallow biopsy of melanoma in situ carries a significant risk of underestimating the true depth of the lesion, as it may harbor focal microinvasion that was not sampled by the superficial technique, according to the National Comprehensive Cancer Network 3, 4
Shave biopsies may compromise pathologic diagnosis and complete assessment of Breslow thickness, particularly when the index of suspicion should have been higher, as noted by the National Comprehensive Cancer Network 5, 4

If clinical evaluation suggests the initial biopsy was inadequate for microstaging, the National Comprehensive Cancer Network recommends performing a narrow-margin excision to obtain deeper tissue before proceeding to wide excision 5, 4
For confirmed melanoma in situ, standard margins are 0.5-1.0 cm measured clinically at the time of surgery, as recommended by the American Academy of Dermatology 1, 7, 2
For lentigo maligna type specifically, surgical margins greater than 0.5 cm may be necessary to achieve histologically negative margins due to subclinical extension, according to the National Comprehensive Cancer Network 5, 4, 2

The American Academy of Dermatology recommends that sentinel lymph node biopsy should be performed before wide excision if the tumor is found to be invasive on re-excision 1, 2

For lentigo maligna melanoma in situ on cosmetically sensitive areas, Mohs micrographic surgery or staged excision with permanent sections may be utilized for tissue-sparing excision and exhaustive histologic assessment of peripheral margins, as recommended by the American Academy of Dermatology 1, 2
Permanent section analysis of the central debulking specimen is mandatory to identify potential invasive melanoma, as sampling error can miss microinvasion, according to the American Academy of Dermatology and the British Journal of Dermatology 1, 6, 2

The pathology report from any re-excision should include Breslow thickness in millimeters, presence or absence of ulceration, mitotic rate per mm², peripheral and deep margin status, and Clark level (optional for Breslow >1 mm), as recommended by the National Comprehensive Cancer Network 5, 7
The specimen must be read by a pathologist experienced in pigmented lesions, according to the National Comprehensive Cancer Network 5, 4